Androgen signaling in prostate cancer

Cold Spring Harbor Perspectives in Medicine

Volumn 7, Issue 9, 2017, Pages

  Dai, Charles ^a,b   Heemers, Hannelore ^a,b,c   Sharifi, Nima ^a,b,c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; LIGAND; TRANSCRIPTION FACTOR;

ANDROGEN SYNTHESIS; ARTICLE; HORMONE STRUCTURE; HUMAN; MALE; PROSTATE CANCER; SIGNAL TRANSDUCTION; ANIMAL; DISEASE EXACERBATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROSTATE TUMOR;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 85025088881     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a030452     Document Type: Article

References (196)

1. AdenijiAO, Chen M, Penning TM. 2013. AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol 137: 136-149.
2. Agoulnik IU, Weigel NL. 2009. Coactivator selective regulation of androgen receptor activity. Steroids 74: 669-674.
3. An J, Wang C, Deng Y, Yu L, Huang H. 2014. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep 6: 657-669.
4. Andersson S, Berman DM, Jenkins EP, Russell DW. 1991. Deletion of steroid 5 a-reductase 2 gene in male pseudohermaphroditism. Nature 354: 159-161.
5. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al. 2014. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371: 1028-1038.
6. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, et al. 2013. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial. Lancet Oncol 14: 1307-1316.
7. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, et al. 2013. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155: 1309-1322.
8. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, et al. 2014. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510: 278-282.
9. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, et al. 2016. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol Cancer Res 14: 324-331.
10. Askew EB, Gampe RT, Stanley TB, Faggart JL, Wilson EM. 2007. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 282: 25801-25816.
11. Attard G, Swennenhuis JF, Olmos D, Reid AHM, Vickers E, A’Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, et al. 2009. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69: 2912-2918.
12. Attard G, Reid AHM, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, et al. 2012. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97: 507-516.
13. Azzouni F, Mohler J. 2012. Role of 5a-reductase inhibitors in prostate cancer prevention and treatment. Urology 79: 1197-1205.
14. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. 2013. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2: e00499.
15. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, et al. 2012. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44: 685-689.
16. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, et al. 2014. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371: 424-433.
17. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. 2011. The genomic complexity of primary human prostate cancer. Nature 470: 214-220.
18. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO. 1998. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol 12: 1172-1183.
19. Bruchovsky N, Wilson JD. 1968. The intranuclear binding of testosterone and 5-a-androstan-17-b-ol-3-one by rat prostate. J Biol Chem 243: 5953-5960.
20. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. 2001. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7: 1273-1281.
21. Byrns MC, Jin Y, Penning TM. 2011. Inhibitors of type 5 17b-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights. J Steroid Biochem Mol Biol 125: 95-104.
22. Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, et al. 2014. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5: 1646-1656.
23. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, et al. 2009. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
24. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM. 1996. Role of CBP/P300 in nuclear receptor signalling. Nature 383: 99-103.
25. Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM. 2015. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res 43: 5880-5897.
26. Chang KH, Sharifi N. 2012. Prostate cancer-from steroid transformations to clinical translation. Nat Rev Urol 9: 721-724.
27. Chang CS, Kokontis J, Liao ST. 1988. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240: 324-326.
28. Chang K-H, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N. 2011. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci 108: 13728-13733.
29. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, et al. 2013. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154: 1074-1084.
30. Claessens F, Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W. 2001. Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid BiochemMol Biol 76: 23-30.
31. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A. 2008. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal 6: e008.
32. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. 1993. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541-1550.
33. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, et al. 1999. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression inanewmodel system. Br JCancer 81: 242-251.
34. Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hessein M, Hsing M, Singh K, LeBlanc E, et al. 2014. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem 289: 26417-26429.
35. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DAL, Tindall DJ. 2003. p300 in prostate cancer proliferation and progression. Cancer Res 63: 7638-7640.
36. de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, et al. 2007. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naı¨ve patients with hormone-refractory prostate cancer. J Clin Oncol 25: 257-262.
37. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, et al. 2011. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005.
38. Decker B, Ostrander EA. 2014. Dysregulation of the homeobox transcription factor gene HOXB13: Role in prostate cancer. Pharmgenomics Pers Med 7: 193-201.
39. Dehm SM, Tindall DJ. 2006. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99: 333-344.
40. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. 2008. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477.
41. Dellis A, Papatsoris AG. 2016. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer. Expert Opin Investig Drugs 1-11.
42. DePriest AD, Fiandalo MV, Schlanger S, Heemers F, Mohler JL, Liu S, Heemers HV. 2016. Regulators of androgen action resource: A one-stop shop for the comprehensive study of androgen receptor action. Database (Oxford) doi: 10.1093/database/bav125.
43. Deslypere JP, Young M, Wilson JD, McPhaul MJ. 1992. Testosterone and 5 a-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 88: 15-22.
44. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J. 1997. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36: 1052-1064.
45. Dunn JF, Nisula BC, Rodbard D. 1981. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 53: 58-68.
46. Dutt SS, Gao AC. 2009. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 5: 1403-1413.
47. Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 2010. 3b-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151: 3514-3520.
48. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, et al. 2012. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366: 141-149.
49. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. 2015. Targeting the androgen receptor pathway in castrationresistant prostate cancer: Progresses and prospects. Oncogene 34: 1745-1757.
50. Fiandalo MV, Wilton J, Mohler JL. 2014. Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment. Int J Biol Sci 10: 596-601.
51. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS. 2012. Dutasteride in localized prostate cancer management: The REDEEM randomised, double-blind, placebo-controlled trial. Lancet 379: 1103-1111.
52. Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Costantini A, Serio M, Martini L. 1989. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: Effects on tissue androgen concentration, 5a-reductase activity and androgen receptor content. J Clin Endocrinol Metab 68: 461-468.
53. Geissler WM, Davis DL, Wu L, Bradshaw KD, Patel S, Mendonca BB, Elliston KO, Wilson JD, Russell DW, Andersson S. 1994. Male pseudohermaphroditism caused by mutations of testicular 17b-hydroxysteroid dehydrogenase 3. Nat Genet 7: 34-39.
54. Geller J, Albert J, LozaD, Geller S, StoeltzingW, de la VegaD. 1978. DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 46: 440-444.
55. Gelmann EP. 2002. Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015.
56. Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Rajendran M, Chew SA, Zimmermann M, et al. 2014. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res 74: 5631-5643.
57. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. 2001. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85: 1928-1936.
58. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. 2012. The mutational landscape of lethal castrationresistant prostate cancer. Nature 487: 239-243.
59. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. 1998. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58: 5718-5724.
60. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. 2001. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892-2898.
61. Griffin JE. 1992. Androgen resistance—The clinical and molecular spectrum. N Engl J Med 326: 611-618.
62. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, et al. 2006. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10: 309-319.
63. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, et al. 2009. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
64. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. 2003. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63: 149-153.
65. He B, Kemppainen JA, Wilson EM. 2000. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275: 22986-22994.
66. He B, Minges JT, Lee LW, Wilson EM. 2002. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 277: 10226-10235.
67. Hearn JW, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang K-H, Carlson R, Rangel L, Reagan K, Davis BJ, et al. 2016. HSD3B1 and resistance to androgen deprivation therapy in prostate cancer: A multi-cohort study. Lancet Oncol 17: 1435-1444.
68. Heemers HV. 2014. Targeting androgen receptor action for prostate cancer treatment: Does the post-receptor level provide novel opportunities? Int J Biol Sci 10: 576-587.
69. Heemers HV, Tindall DJ. 2007. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28: 778-808.
70. Heemers HV, Tindall DJ. 2009. Unraveling the complexities of androgen receptor signaling in prostate cancer cells. Cancer Cell 15: 245-247.
71. Heemers HV, Regan KM, Schmidt LJ, Anderson SK, Ballman KV, Tindall DJ. 2009. Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol 23: 572-583.
72. Heemers HV, Schmidt LJ, Kidd E, Raclaw KA, Regan KM, Tindall DJ. 2010. Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells. Prostate 70: 959-970.
73. Heery DM, Kalkhoven E, Hoare S, Parker MG. 1997. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736.
74. Hofland J, van Weerden WM, Dits NFJ, Steenbergen J, van Leenders GJLH, Jenster G, Schröder FH, de Jong FH. 2010. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70: 1256-1264.
75. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, et al. 2004. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164: 217-227.
76. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al. 2009. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
77. Huggins C, Hodges CV. 1941. Studies on prostatic cancer. I: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297.
78. Ianculescu I, Wu DY, Siegmund KD, Stallcup MR. 2012. Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells. J Biol Chem 287: 4000-4013.
79. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. 1974. Steroid 5a-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 186: 1213-1215.
80. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO. 1991. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5: 1396-1404.
81. Kaku N, Matsuda K, Tsujimura A, Kawata M. 2008. Characterization of nuclear import of the domain-specific androgen receptor in association with the importin a/ b and Ran-Guanosine 50-triphosphate systems. Endocrinology 149: 3960-3969.
82. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, et al. 2009. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526.
83. Knudsen KE. 2014. Hormone whodunit: Clues for solving the case of intratumor androgen production. Clin Cancer Res 20: 5343-5345.
84. Knudsen KE, Scher HI. 2009. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15: 4792-4798.
85. Labrie F, Dupont A, Simard J, Luu-The V, Bélanger A. 1993. Intracrinology: The basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 24: 94-105.
86. Lamont KR, Tindall DJ. 2011. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 25: 897-907.
87. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. 2011. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71: 2108-2117.
88. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM. 2012. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31: 4759-4767.
89. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KAT, Dehm SM. 2013. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73: 483-489.
90. Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N. 2015. Conversion of abiraterone to D4Adrives anti-tumour activity in prostate cancer. Nature 523: 347-351.
91. Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N. 2016. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533: 547-551.
92. Li J, Alyamani M, Zhang A, Chang K-H, Berk M, Li Z, Zhu Z, Petro M, Magi-Galluzzi C, Taplin M-E, et al. 2017. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. eLife doi: 10.7554/eLife.20183.
93. Liao RS, Ma S, Miao L, Li R, Yin Y, Raj GV. 2013. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol 2: 187-196.
94. Lin C, Yang L, Tanasa B, Hutt K, Ju B, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, et al. 2009. Nuclear receptor-induced chromosomal proximity andDNA breaks underlie specific translocations in cancer. Cell 139: 1069-1083.
95. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X. 2014. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33: 3140-3150.
96. Lösel R, Wehling M. 2003. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4: 46-56.
97. Lu J, Van der Steen T, Tindall DJ. 2015. Are androgen receptor variants a substitute for the full-length receptor? Nat Rev Urol 12: 137-144.
98. Lubahn DB, Brown TR, Simental JA, Higgs HN, Migeon CJ, Wilson EM, French FS. 1989. Sequence of the intron/ exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci 86: 9534-9538.
99. Mani R-S, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. 2009. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326: 1230.
100. Marks LS. 2004. 5a-reductase: History and clinical importance. Rev Urol 6: S11-S21.
101. Marshall TW, Link KA, Petre-Draviam CE, Knudsen KE. 2003. Differential requirement of SWI/SNF for androgen receptor activity. J Biol Chem 278: 30605-30613.
102. Maughan BL, Antonarakis ES. 2015. Clinical relevance of androgen receptor splice variants in castration-resistant prostate cancer. Curr Treat Options Oncol 16: 57.
103. McMullin RP, Dobi A, Mutton LN, Orosz A, Maheshwari S, Shashikant CS, Bieberich CJ. 2010. A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland. Proc Natl Acad Sci 107: 98-103.
104. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. 2004. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527.
105. Mills IG. 2014. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 14: 187-198.
106. Mohler JL. 2008. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 617: 223-234.
107. Mohler JL, Gregory CW, Ford OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS. 2004. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440-448.
108. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, et al. 2012. Prostate cancer, Version 3. 2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10: 1081-107.
109. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. 2008. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454.
110. Mostaghel EA. 2013. Steroid hormone synthetic pathways in prostate cancer. Transl Androl Urol 2: 212-227.
111. Mostaghel EA. 2014a. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res 6: 39-51.
112. Mostaghel EA. 2014b. Beyond T and DHT—Novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci 10: 602-613.
113. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, et al. 2007. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67: 5033-5041.
114. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB. 2011. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17: 5913-5925.
115. Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, et al. 2014. Targeted androgen pathway suppression in localized prostate cancer: A pilot study. J Clin Oncol 32: 229-237.
116. Nakamura Y, Hornsby PJ, Casson P, Morimoto R, Satoh F, Xing Y, Kennedy MR, Sasano H, Rainey WE. 2009. Type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. J Clin Endocrinol Metab 94: 2192-2198.
117. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. 2002. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci 99: 11890-11895.
118. Ni L, Llewellyn R, Kesler CT, Kelley JB, Spencer A, Snow CJ, Shank L, Paschal BM. 2013. Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. Mol Cell Biol 33: 4766-4778.
119. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. 2010. The human glucocorticoid receptor: Molecular basis of biologic function. Steroids 75: 1-12.
120. Nishiyama T. 2014. Serum testosterone levels after medical or surgical androgen deprivation: A comprehensive review of the literature. Urol Oncol 32: 38. e17-28.
121. Nishiyama T, Hashimoto Y, Takahashi K. 2004. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10: 7121-7126.
122. Nuclear Receptors Nomenclature Committee. 1999. A unified nomenclature system for the nuclear receptor superfamily. Cell 97: 161-163.
123. Ozanne DM, Brady ME, Cook S, Gaughan L, Neal DE, Robson CN. 2000. Androgen receptor nuclear translocation is facilitated by the F-actin cross-linking protein filamin. Mol Endocrinol 14: 1618-1626.
124. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. 2006. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91: 3850-3856.
125. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM. 2011. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: A randomized-controlled trial. J Clin Endocrinol Metab 96: 430-437.
126. Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA. 2014. TMPRSS2: ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol 32: 206-211.
127. Pedram A, Razandi M, Sainson RCA, Kim JK, Hughes CC, Levin ER. 2007. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 282: 22278-22288.
128. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, et al. 2007. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 31: 882-888.
129. Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, Cejas P, Vazquez F, Cook J, Shivdasani RA, et al. 2015a. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet 47: 1346-1351.
130. Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, Cejas P, Vazquez F, Cook J, Shivdasani RA, et al. 2015b. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet 47: 1346-1351.
131. Ponguta LA, Gregory CW, French FS, Wilson EM. 2008. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem 283: 20989-21001.
132. Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV. 2013. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun 4: 1923. Rittmaster RS. 1997. 5a-reductase inhibitors. J Androl 18: 582-587.
133. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R. 2008. Effect of dutasteride on intraprostatic androgen levels in menwith benign prostatic hyperplasia or prostate cancer. Urology 72: 808-812.
134. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al. 2015. Integrative clinical genomics of advanced prostate cancer. Cell 161: 1215-1228.
135. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. 1991. Sex hormone-binding globulin: Anatomy and physiology of a new regulatory system. J Steroid Biochem Mol Biol 40: 813-820.
136. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schröder FH, van derKwast TH. 1994. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144: 735-746.
137. Russell DW, Wilson JD. 1994. Steroid 5a-reductase: Two genes/two enzymes. Annu Rev Biochem 63: 25-61.
138. Ryan CJ, Tindall DJ. 2011. Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29: 3651-3658.
139. Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, Gerald W, Scher HI. 2006. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression. Urology 68: 834-839.
140. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, et al. 2015. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naı¨ve men with metastatic castration-resistant prostate cancer (COUAA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16: 152-160.
141. Sadi MV, Walsh PC, Barrack ER. 1991. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67: 3057-3064.
142. Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, Hautaniemi S, Janne OA. 2013. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res 73: 1570-1580.
143. Scher HI, Kelly WK. 1993. Flutamidewithdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11: 1566-1572.
144. Scher HI, Sawyers CL. 2005. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261.
145. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187-1197.
146. Schmidt LJ, Tindall DJ. 2011. Steroid 5a-reductase inhibitors targeting BPH and prostate cancer. J Steroid Biochem Mol Biol 125: 32-38.
147. Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R. 2013. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: Results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer. Eur Urol 63: 779-787.
148. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. 2004. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci 101: 4758-4763.
149. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL. 2009. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol 181: 621-626.
150. Sharifi N. 2010. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Expert Opin Investig Drugs 19: 837-846.
151. Sharifi N. 2013. Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology 154: 4010-4017.
152. Sharifi N. 2014. Steroid receptors aplenty in prostate cancer. N Engl J Med 370: 970-971.
153. Sharifi N, Auchus RJ. 2012. Steroid biosynthesis and prostate cancer. Steroids 77: 719-726.
154. Sharifi N, Gulley JL, Dahut WL. 2005. Androgen deprivation therapy for prostate cancer. JAMA 294: 238-244.
155. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, et al. 2013. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23: 35-47.
156. Shiota M, Yokomizo A, Fujimoto N, Naito S. 2011. Androgen receptor cofactors in prostate cancer: Potential therapeutic targets of castration-resistant prostate cancer. Curr Cancer Drug Targets 11: 870-881.
157. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH. 2005. Molecular biology of the 3b-hydroxysteroid dehydrogenase/D5-D4 isomerase gene family. Endocr Rev 26: 525-582.
158. Simental JA, Sar M, Lane MV, French FS, Wilson EM. 1991. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266: 510-518.
159. Smith DF, Toft DO. 2008. Minireview: The intersection of steroid receptors with molecular chaperones: Observations and questions. Mol Endocrinol 22: 2229-2240.
160. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
161. Steers WD. 2001. 5a-reductase activity in the prostate. Urology 58: 17-24; discussion 24.
162. Sun S, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, et al. 2010. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
163. Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD. 2012. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate 72: 157-164.
164. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398.
165. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59: 2511-2515.
166. Taplin M-E, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, et al. 2003. Androgen receptor mutations in androgenindependent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21: 2673-2678.
167. Taplin M-E, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, et al. 2014. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study. J Clin Oncol 32: 3705-3715.
168. Thadani-Mulero M, Nanus DM, Giannakakou P. 2012. Androgen receptor on the move: Boarding the microtubule expressway to the nucleus. Cancer Res 72: 4611-4615.
169. The Cancer Genome Atlas Research Network. 2015. The molecular taxonomy of primary prostate cancer. Cell 163: 1011-1025.
170. Thigpen AE, Cala KM, Russell DW. 1993. Characterization of Chinese hamster ovary cell lines expressing human steroid 5a-reductase isozymes. J Biol Chem 268: 17404-17412.
171. Thirumalai A, Cooper LA, Rubinow KB, Amory JK, Lin DW, Wright JL, Marck BT, Matsumoto AM, Page ST. 2016. Stable intraprostatic dihydrotestosterone in healthy medically castrate men treated with exogenous testosterone. J Clin Endocrinol Metab 101: 2937-2944.
172. Thomas LN, Douglas RC, Lazier CB, Too CKL, Rittmaster RS, Tindall DJ. 2008. Type 1 and type 2 5a-reductase expression in the development and progression of prostate cancer. Eur Urol 53: 244-252.
173. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. 1989. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci 86: 327-331.
174. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. 2005. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653-4657.
175. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, et al. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
176. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. 2009. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 56: 275-286.
177. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al. 2009. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790.
178. Umesono K, Evans RM. 1989. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57: 1139-1146.
179. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E. 1992. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665-669.
180. Wallén MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. 1999. Androgen receptor gene mutations in hormonerefractory prostate cancer. J Pathol 189: 559-563.
181. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al. 2009. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
182. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA, et al. 2011a. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474: 390-394.
183. Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, O’Malley BW. 2011b. Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol 25: 2041-53.
184. Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, Wang J, Qi R, Matzuk AJ, Song X, Madoux F, et al. 2014. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivatorsSRC-3 andSRC-1. CancerRes 74:1506-1517.
185. Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. 2014. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer 21: T87-T103.
186. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. 2010. Constitutively active androgen receptor splice variants expressed in castrationresistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci 107: 16759-16765.
187. Wilson JD. 2001. The role of 5a-reduction in steroid hormone physiology. Reprod Fertil Dev 13: 673-678.
188. Wilson EM, French FS. 1976. Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem 251: 5620-5629.
189. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. 2006. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12: 4072-4079.
190. Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, Gambhir SS, Lee P, Sartor O, Flemington EK, et al. 2015. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res 75: 3663-3671.
191. Zhang A, Zhang J, Plymate S, Mostaghel EA. 2016. Classical and non-classical roles for pre-receptor control of DHT metabolism in prostate cancer progression. Horm Cancer 7: 104-113.
192. Zhao Y, Tindall DJ, Huang H. 2014. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci 10: 614-619.
193. Zhou ZX, LaneMV, Kemppainen JA, French FS, Wilson EM. 1995. Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9: 208-218.
194. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY, Tsai MJ. 2005. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65: 7976-7983.
195. Zhu YS, Imperato-McGinley JL. 2009. 5a-reductase isozymes and androgen actions in the prostate. Ann NY Acad Sci 1155: 43-56
196. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED. 2004. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332-337.